Valium Shortage: What Providers and Prescribers Need to Know in 2026

Diazepam (Valium) availability disruptions are a recurring clinical challenge that intersects patient safety, prescribing regulations, and supply chain dynamics. While oral diazepam tablets are not under a formal FDA-declared nationwide shortage as of 2026, prescribers continue to encounter patients who report difficulty filling their prescriptions — and injectable diazepam has experienced documented shortage periods affecting hospital and clinical settings. This briefing provides a comprehensive overview of the current supply landscape, clinical substitution guidance, and practical management strategies.

Current Supply Landscape (2026)

Oral diazepam tablets (2 mg, 5 mg, 10 mg) are manufactured by multiple generic companies and are generally available through major wholesalers. However, patients and pharmacists report intermittent localized stock-outs, particularly for specific strengths or specific generic manufacturers' products. Injectable diazepam (IV/IM formulations) has experienced ongoing shortage periods tracked by ASHP and UUDIS, with parenteral benzodiazepine shortages historically having median durations exceeding 500 days.

Valtoco (diazepam nasal spray, Neurelis) and Diastat (rectal gel) are brand-name or limited-generic formulations with more concentrated distribution, making them potentially harder to source at smaller pharmacies. For patients requiring these formulations (seizure rescue therapy), this can present a more acute clinical concern.

Root Causes of Diazepam Availability Gaps

Understanding the structural drivers helps prescribers communicate effectively with patients and make anticipatory prescribing decisions:

• DEA Aggregate Production Quotas (APQ): Schedule IV controlled substances are subject to annual APQs. These quotas can lag behind changes in prescribing trends, creating supply ceilings that manufacturers cannot legally exceed even when demand spikes.
• Post-pandemic demand surge: Benzodiazepine prescriptions rose sharply during and after COVID-19. While prescribing has stabilized, the residual elevated demand continues to stress production capacity.
• API supply chain concentration: The active pharmaceutical ingredients for diazepam are largely produced overseas. Manufacturing disruptions or regulatory actions at overseas facilities can ripple into domestic supply.
• Wholesale allocation limits: Wholesalers (AmerisourceBergen, McKesson, Cardinal Health) may limit the quantity of a controlled substance a given pharmacy can order per period. Pharmacies that have reached their allocation ceiling cannot reorder even when their shelves are empty.

Key Safety Concern: Benzodiazepine Withdrawal

The most critical clinical concern in any diazepam availability disruption is the risk of unintended abrupt discontinuation. Benzodiazepine withdrawal syndrome can be life-threatening, manifesting as:

• Grand mal seizures
• Hallucinations and psychosis
• Severe anxiety, panic, and agitation
• Tremors, diaphoresis, hypertension
• Delirium (especially in elderly patients or high-dose users)

Given diazepam's exceptionally long half-life (~48 hours for the parent compound, up to 100 hours for the active metabolite N-desmethyldiazepam), acute withdrawal may be delayed by several days after the last dose. This can lull both patients and clinicians into a false sense of security. Patients with long-term, high-dose diazepam use are at particular risk.

Benzodiazepine Substitution Equivalencies

If diazepam is unavailable and a therapeutic switch is clinically appropriate, the following approximate equivalencies are commonly used in the literature. These are estimates — individual patient response varies and clinical judgment should guide conversion:

• Diazepam 5 mg ≈ Lorazepam 1 mg ≈ Clonazepam 0.5 mg ≈ Alprazolam 0.5 mg ≈ Oxazepam 15 mg

Key clinical considerations when switching from diazepam:

• Lorazepam has no active metabolites and is preferred in hepatic impairment and elderly patients. However, its shorter half-life (10-20 hours) means more frequent dosing and potentially greater interdose anxiety. Note that lorazepam oral tablets have also experienced localized shortages.
• Clonazepam is long-acting (half-life 18-50 hours) and generally well-tolerated. Good option for anxiety and seizure patients. Available as generic.
• Oxazepam is pharmacologically straightforward with no active metabolites; particularly useful for elderly patients and those with liver disease. Its slower onset may be suboptimal for acute anxiety.

Prescribing Strategies to Improve Access

The following prescribing and communication practices can reduce the likelihood of patients experiencing critical supply gaps:

1. Write prescriptions 1-2 weeks early. Federal law allows Schedule IV prescriptions to be filled as early as the refill date permits. Encourage patients not to wait until their last few days of medication before refilling.
2. Consider 90-day supplies. Where state and payer rules allow, 90-day supplies via mail-order pharmacies reduce the frequency of fill events and exposure to localized stock-outs.
3. Document a backup plan in the chart. Note an acceptable alternative agent and dose equivalence so that any on-call provider can act quickly if a patient calls in crisis about supply.
4. Direct patients to medfinder.
5. Proactively counsel at-risk patients. Long-term, high-dose diazepam users — especially those on it for seizure control or alcohol use disorder — are at greatest risk from supply disruptions. Proactive counseling about what to do if they can't fill their prescription is an important safety intervention.

Telehealth and Controlled Substance Prescribing

As of 2026, telehealth prescribing rules for Schedule IV controlled substances vary by state. Many states allow Schedule IV prescribing via telehealth with an established patient relationship. The DEA has continued to evaluate post-pandemic telehealth prescribing rules. Prescribers should check their state medical board's current guidelines and the DEA's telehealth prescribing framework before prescribing diazepam via telemedicine.

Resources for Your Practice

medfinder offers a provider-facing service to help your patients locate medications. Visit medfinder.com/providers to learn how medfinder can support your patients in finding diazepam and other medications in stock near them.